Editas Medicine (EDIT) Competitors $2.03 -0.07 (-3.33%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$2.06 +0.03 (+1.48%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT vs. TSHA, IOVA, TRVI, KROS, BCAX, STOK, MAZE, MNMD, BCYC, and UPBShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Taysha Gene Therapies (TSHA), Iovance Biotherapeutics (IOVA), Trevi Therapeutics (TRVI), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), Stoke Therapeutics (STOK), Maze Therapeutics (MAZE), Mind Medicine (MindMed) (MNMD), Bicycle Therapeutics (BCYC), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. Its Competitors Taysha Gene Therapies Iovance Biotherapeutics Trevi Therapeutics Keros Therapeutics Bicara Therapeutics Stoke Therapeutics Maze Therapeutics Mind Medicine (MindMed) Bicycle Therapeutics Upstream Bio Taysha Gene Therapies (NASDAQ:TSHA) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, community ranking, earnings, risk, institutional ownership, dividends and valuation. Does the media favor TSHA or EDIT? In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 15 articles in the media. Editas Medicine's average media sentiment score of 1.24 beat Taysha Gene Therapies' score of 0.78 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, TSHA or EDIT? Taysha Gene Therapies has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Does the MarketBeat Community believe in TSHA or EDIT? Editas Medicine received 200 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 79.05% of users gave Taysha Gene Therapies an outperform vote while only 53.46% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformTaysha Gene TherapiesOutperform Votes11779.05% Underperform Votes3120.95% Editas MedicineOutperform Votes31753.46% Underperform Votes27646.54% Is TSHA or EDIT more profitable? Taysha Gene Therapies has a net margin of -229.67% compared to Editas Medicine's net margin of -340.96%. Editas Medicine's return on equity of -80.13% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-229.67% -106.36% -49.16% Editas Medicine -340.96%-80.13%-50.99% Do analysts prefer TSHA or EDIT? Taysha Gene Therapies currently has a consensus price target of $7.57, indicating a potential upside of 183.57%. Editas Medicine has a consensus price target of $5.36, indicating a potential upside of 164.22%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Taysha Gene Therapies is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Editas Medicine 2 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.29 Which has higher valuation and earnings, TSHA or EDIT? Taysha Gene Therapies has higher earnings, but lower revenue than Editas Medicine. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$7.22M79.34-$111.57M-$0.34-7.85Editas Medicine$35.84M4.74-$153.22M-$3.04-0.67 Do institutionals & insiders have more ownership in TSHA or EDIT? 77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by insiders. Comparatively, 2.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryTaysha Gene Therapies beats Editas Medicine on 12 of the 18 factors compared between the two stocks. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$175.80M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-0.7933.3227.1420.06Price / Sales4.74469.84411.98157.10Price / CashN/A168.6838.2534.64Price / Book0.483.457.064.70Net Income-$153.22M-$72.35M$3.23B$247.88M7 Day Performance12.78%6.23%2.85%2.63%1 Month Performance31.82%16.53%9.06%6.36%1 Year Performance-66.39%-16.90%31.43%14.05% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.2821 of 5 stars$2.03-3.3%$5.36+164.2%-62.6%$175.80M$35.84M-0.79230Positive NewsAnalyst RevisionTSHATaysha Gene Therapies3.8529 of 5 stars$2.81+0.9%$7.57+169.1%-28.8%$610.71M$7.22M4.52180Analyst ForecastAnalyst RevisionIOVAIovance Biotherapeutics4.6591 of 5 stars$1.82+3.1%$13.30+632.8%-74.0%$606.09M$212.68M-1.22500Trending NewsTRVITrevi Therapeutics3.5 of 5 stars$6.06-4.2%$18.63+207.6%+140.4%$604.35MN/A-13.7520High Trading VolumeKROSKeros Therapeutics3.6614 of 5 stars$14.87+1.4%$37.00+148.8%-71.2%$604.35M$214.71M-2.86100Analyst DowngradeBCAXBicara Therapeutics2.3353 of 5 stars$11.04+11.5%$31.86+188.5%N/A$600.66MN/A0.0032Analyst RevisionHigh Trading VolumeSTOKStoke Therapeutics3.9096 of 5 stars$10.83+9.3%$23.20+114.2%-27.4%$592.60M$190.91M-5.17100Analyst RevisionMAZEMaze TherapeuticsN/A$13.35+10.3%$25.67+92.3%N/A$584.69M$167.50M0.00121MNMDMind Medicine (MindMed)1.9908 of 5 stars$7.70+3.0%$25.11+226.1%-1.7%$582.14MN/A-3.4140News CoveragePositive NewsAnalyst RevisionBCYCBicycle Therapeutics3.3664 of 5 stars$8.38-2.0%$25.00+198.3%-63.1%$579.66M$25.72M-2.54240News CoverageAnalyst RevisionUPBUpstream Bio1.9399 of 5 stars$10.78+1.1%$56.50+424.0%N/A$579.04M$2.30M0.0038 Related Companies and Tools Related Companies Taysha Gene Therapies Competitors Iovance Biotherapeutics Competitors Trevi Therapeutics Competitors Keros Therapeutics Competitors Bicara Therapeutics Competitors Stoke Therapeutics Competitors Maze Therapeutics Competitors Mind Medicine (MindMed) Competitors Bicycle Therapeutics Competitors Upstream Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDIT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
